Home     About Us     Team     Products     News     Contact     FAQ     Account

BCR-ABL Tyrosine Kinase Inhibitors

Bosulif (bosutinib)

Bosutinib (trade name Bosulif) received US FDA and EU European Medicines Agency approval on September 4, 2012 and 27 March 2013 respectively for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy...Wikipedia

 

 

Manufacturer's Website: Bosulif                                                                                                                        Average retail cost:   $5,200/month

Iclusig (ponatinib)

Ponatinib (trade name Iclusig) is an oral drug developed by ARIAD Pharmaceuticals for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL)...Wikipedia

 

 

Manufacturer's Website: Iclusig                                                                                                                        Average retail cost:   $5,400/month

Gleevec (imatinib)

Imatinib, sold under the brand names Gleevec among others, is a chemotherapy medication used to treat cancer. Specifically, it is used for chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL) that is Philadelphia chromosome-positive (Ph+) and certain types of gastrointestinal stromal tumors (GIST), systemic mastocytosis, and myelodysplastic syndrome. It is taken by mouth...Wikipedia

 

 

Manufacturer's Website: Gleevec                                                                                                                        Average retail cost:   $10,300/month

Tasigna (nilotinib)

Nilotinib (AMN107, trade name Tasigna), in the form of the hydrochloride monohydrate salt, is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia...Wikipedia

 

 

Manufacturer's Website: Tasigna                                                                                                                        Average retail cost:   $10,600/month

Braftovi (encorafenib) & Mektovi (binimetinib)

In June 2018, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) were approved by the FDA for the treatment of people with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma...Wikipedia

 

 

Manufacturer's Website: Braftovi+Mektovi                                                                                                                      Average retail cost:   $11,633/month

Sprycel (dasatinib)

Dasatinib is a medication used primarily to treat chronic myelogenous leukemia and selected cases of acute lymphoblastic leukemia. It is produced by Bristol-Myers Squibb and sold under the trade name Sprycel. Dasatinib is a Bcr-Abl (the "Philadelphia chromosome") and Src family tyrosine kinase inhibitor approved for first line use in people with chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)...Wikipedia

 

 

Manufacturer's Website: Sprycel                                                                                                                       Average retail cost:   $12,300/month

Copyright 2006-2020 Automated Clinical Guidelines, LLC. All rights reserved.

â„¢